Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T lymphocytes MDG1015
Term · Oncology and biomedicine · MLC-T-ONC-011724
A preparation of autologous T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), and a programmed cell death protein 1 (PD-1; PDCD1; CD279)-4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) costimulatory switch protein (CSP), with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T lymphocytes MDG1015 specifically targets and binds to NY-ESO-1 and/or LAGE-1A expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing NY-ESO-1 and/or LAGE-1A. In addition, upon binding of the TCR-T cells MDG1015 to NY-ESO-1 and/or LAGE-1A expressed on tumor cells, the PD-1-4-1BB CSP is activated. This abrogates PD-1-mediated signaling in T cells and PD-1-mediated T-cell inhibition, and activates 4-1BB signaling locally in the tumor microenvironment (TME), which enhances the activity and persistence of the TCR-T cells MDG1015. NY-ESO-1 and LAGE-1A, members of the CTA family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*02:01 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.
| Identifier | MLC-T-ONC-011724 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-T cells MDG1015; autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR/PD-1-4-1BB costimulatory switch protein-expressing T cells MDG1015 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011724",
"term": "Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T lymphocytes MDG1015",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), and a programmed cell death protein 1 (PD-1; PDCD1; CD279)-4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) costimulatory switch protein (CSP), with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T lymphocytes MDG1015 specifically targets and binds to NY-ESO-1 and/or LAGE-1A expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing NY-ESO-1 and/or LAGE-1A. In addition, upon binding of the TCR-T cells MDG1015 to NY-ESO-1 and/or LAGE-1A expressed on tumor cells, the PD-1-4-1BB CSP is activated. This abrogates PD-1-mediated signaling in T cells and PD-1-mediated T-cell inhibition, and activates 4-1BB signaling locally in the tumor microenvironment (TME), which enhances the activity and persistence of the TCR-T cells MDG1015. NY-ESO-1 and LAGE-1A, members of the CTA family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*02:01 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.",
"synonyms": [
"autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-T cells MDG1015",
"autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR/PD-1-4-1BB costimulatory switch protein-expressing T cells MDG1015"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-ny-eso-1-lage-1a-specific-hla-a-02-01-restricted-tcr-expressing-t/"
}
Record 3,060 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.